Table 3.
Univariate and multivariate analyses of the overall survival in the subgroup of patients who had received perioperative therapy with prior (neo) adjuvant anthracycline- and/or taxane-based regimens (Cox hazard model)
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age ≥ 60 years | 1.22 | 0.83–1.78 | 0.31 | |||
| Estrogen receptor negative | 1.20 | 0.81–1.77 | 0.37 | 1.99 | 1.14–3.46 | 0.015 |
| Central nervous system metastasis | 1.20 | 0.53–2.74 | 0.66 | |||
| Bone metastasis | 1.63 | 1.11–2.37 | 0.012 | 3.28 | 1.84–5.82 | <0.001 |
| Lung metastasis | 1.11 | 0.76–1.63 | 0.59 | |||
| Pleura/lymphangiopathy metastasis | 1.21 | 0.76–1.94 | 0.42 | |||
| Lymph node metastasis | 1.10 | 0.75–1.62 | 0.63 | |||
| Liver metastasis | 1.83 | 1.24-2.70 | 0.002 | 0.72 | 0.36-1.41 | 0.34 |
| Visceral metastasis | 1.74 | 1.14-2.63 | 0.009 | 3.96 | 1.94-8.08 | <0.001 |
| ≥ 3 metastatic sites | 1.39 | 0.95–2.01 | 0.087 | 0.55 | 0.30–1.00 | 0.050 |
| Disease-free interval (< 24 months) | 1.54 | 1.06–2.24 | 0.025 | 1.80 | 1.04-3.10 | 0.035 |
| Therapy | ||||||
| Eribulin vs. non-Eribulin | 0.86 | 0.58-1.30 | 0.48 | |||
| Early line Eribulin a vs. non-Eribulin | 1.01 | 0.65-1.57 | 0.96 | |||
| Late line Eribulin b vs. non-Eribulin | 0.70 | 0.42-1.15 | 0.16 | 0.39 | 0.21-0.70 | 0.002 |
CI: confidence interval, HR: hazard ratio
aEarly line includes first or second lines of therapy
bLate line includes third or later lines of therapy